Press release
Follicular Lymphoma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Mab Works, AstraZeneca, ADC Therapeutics,
Follicular Lymphoma Pipeline Insight
Follicular Lymphoma Pipeline constitutes 50+ key companies continuously working towards developing 55+ Follicular Lymphoma treatment therapies, analyzes DelveInsight.
Follicular Lymphoma Overview:
Follicular lymphoma (FL) is an indolent B-cell non-Hodgkin lymphoma (NHL), accounting for 20-30% of all NHL cases. While not typically curable, FL is often managed as a chronic condition, with patients living for many years post-diagnosis. FL originates from germinal center B-cells and is characterized by abnormal proliferation of malignant B-cells, leading to lymph node enlargement, spleen or bone marrow involvement, and potential spread to other tissues and organs.
The hallmark genetic mutation in FL is the translocation t(14;18)(q32;q21), causing overexpression of BCL2, an anti-apoptotic protein. About 5% of cases involve deregulated BCL6, critical for germinal center formation and transcription regulation. Other implicated genes include those related to cell cycle arrest, such as p21 and p16.
"Follicular Lymphoma Pipeline Insight 2025 [https://www.delveinsight.com/report-store/follicular-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Follicular Lymphoma Therapeutics Market.
Key Takeaways from the Follicular Lymphoma Pipeline Report
*
DelveInsight's Follicular Lymphoma pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Follicular Lymphoma treatment.
*
In August 2025, the company plans to submit a supplemental Biologics License Application (sBLA) for tafasitamab by the end of the year. This application targets the treatment of patients with follicular lymphoma (FL) who have not responded to at least one prior systemic anti-CD20 immunotherapy or chemo-immunotherapy, based on positive Phase III trial results.
*
In June 2025, a consortium led by Eugene Private Equity and Korea Development Bank Private Equity announced the acquisition of an 80% stake in South Korean vaccine manufacturer Boryung Biopharma Co. for 320 billion won (approximately USD 231 million).
*
In February 2025, Incyte revealed it had entered into an asset purchase agreement with MorphoSys AG, granting Incyte exclusive global rights to tafasitamab. Following this agreement, Incyte will assume full responsibility for U.S. commercialization and clinical development, with MorphoSys no longer eligible for milestone payments, profit shares, or royalty payments.
*
Key Follicular Lymphoma companies such as Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron Pharmaceuticals, Pfizer, InnoCare Pharma, TriSalus Life Sciences, BeiGene, and others are evaluating new drugs for Follicular Lymphoma to improve the treatment landscape.
*
Promising Follicular Lymphoma pipeline therapies in various stages of development include MIL62, AZD0486, Abexinostat, ABBV-319, NX-2127, and others.
Follicular Lymphoma Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Follicular Lymphoma Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Follicular Lymphoma treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Follicular Lymphoma market.
Download our free sample page report on Follicular Lymphoma pipeline insights [https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Follicular Lymphoma Emerging Drugs
*
MIL62: MAB WORKS
*
AZD0486: AstraZeneca
*
Abexinostat: Xynomic Pharmaceuticals
*
ABBV-319: AbbVie
*
NX-2127: Nurix Therapeutics, Inc.
Follicular Lymphoma Companies
Over 50 prominent companies are actively working on developing therapies for Follicular Lymphoma. Among these, MAB WORKS and AstraZeneca have drug candidates in the most advanced stage of development, specifically Phase III trials.
DelveInsight's report covers around 22+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Follicular Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Follicular Lymphoma Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Follicular Lymphoma Therapies and Key Companies: Follicular Lymphoma Clinical Trials and advancements [https://www.delveinsight.com/report-store/follicular-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Follicular Lymphoma Pipeline Therapeutic Assessment
- Follicular Lymphoma Assessment by Product Type
- Follicular Lymphoma By Stage
- Follicular Lymphoma Assessment by Route of Administration
- Follicular Lymphoma Assessment by Molecule Type
Download Follicular Lymphoma Sample report to know in detail about the Follicular Lymphoma treatment market @ Follicular Lymphoma Therapeutic Assessment [https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Follicular Lymphoma Current Treatment Patterns
4. Follicular Lymphoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Follicular Lymphoma Late-Stage Products (Phase-III)
7. Follicular Lymphoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Follicular Lymphoma Discontinued Products
13. Follicular Lymphoma Product Profiles
14. Follicular Lymphoma Key Companies
15. Follicular Lymphoma Key Products
16. Dormant and Discontinued Products
17. Follicular Lymphoma Unmet Needs
18. Follicular Lymphoma Future Perspectives
19. Follicular Lymphoma Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Follicular Lymphoma Pipeline Reports Offerings: https://www.delveinsight.com/report-store/follicular-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=follicular-lymphoma-clinical-and-nonclinical-studies-key-companies-therapeutic-assessment-emerging-therapies-treatment-algorithm-and-pipeline-analysis-mab-works-astrazeneca-adc-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Follicular Lymphoma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Mab Works, AstraZeneca, ADC Therapeutics, here
News-ID: 4080529 • Views: …
More Releases from ABNewswire
Uplers Highlights 2025 Trend: Brands Compete to Hire Graphic Designers With Adva …
The design industry is entering a new era in 2025 and the years to come. Creativity and artificial intelligence are merging to reshape how visual content is being produced. For brands, this no longer is a trend to monitor, instead it's a race to secure the right and skilled talent. Companies are fiercely competing to hire graphic designers who can harness AI tools to deliver innovation, speed, and consistency across…
Inside Uplers Latest Report: What Companies Should Know About Angular Developer …
Angular continues to be one of the widely adopted front-end frameworks for dynamic and scalable app development. With digital products becoming increasingly complex, global hiring managers are continuing to face the challenge of finding Angular talent for balancing cost and availability.
In response to this, Uplers is publishing new salary insights based on the evolving hiring trends for supporting companies in shaping their competitive strategies to hire Angular developers [https://www.uplers.com/hire-angularjs-developers/]. The…
The Moss Way: Unlocking the True Power of Irish Sea Moss for Modern Wellness
London, United Kingdom - 7 Oct, 2025 - As the wellness industry evolves, a growing number of people are turning back to nature's timeless remedies - and few are as powerful or as misunderstood as Irish Sea Moss. Leading this natural health renaissance is The Moss Way, a UK-based wellness brand redefining what it means to nourish the body with pure, sustainably sourced superfoods. With a focus on authenticity, science,…
New Outdoor Retailer Feeling My Adventure Empowers Digital Detox Through Compreh …
The outdoor retail sector welcomes Feeling My Adventure, a new e-commerce venture operated by Ingrid K Santana Ramirez LLC, offering comprehensive equipment solutions for camping, survival preparedness, and outdoor recreation activities. Launching at feelingmyadventure.com, the platform distinguishes itself through a philosophy emphasizing nature's role in personal restoration and the importance of disconnecting from digital saturation to rediscover authentic human experiences.
Market timing for the launch aligns with growing societal recognition of…
More Releases for Follicular
Key Trends Reshaping the Follicular Lymphoma Treatment Market: Technological Adv …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Follicular Lymphoma Treatment Market Size Growth Forecast: What to Expect by 2025?
In recent years, there has been robust growth in the size of the follicular lymphoma treatment market. The market is projected to expand from $3.05 billion in 2024 to $3.28 billion in 2025, with a compound annual…
Follicular Lymphoma Market to Reach USD 6.74 Billion by 2034
Follicular lymphoma (FL) is the second most common type of non-Hodgkin lymphoma (NHL), accounting for roughly 20-30% of NHL cases worldwide. It is generally an indolent (slow-growing) B-cell malignancy, but it can transform into aggressive lymphoma in some patients. With advancements in immunotherapy, monoclonal antibodies, and targeted therapies, treatment outcomes have improved, offering patients longer remission periods and better quality of life.
Download Full PDF Sample Copy of Market Report @…
Follicular Lymphoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Follicular Lymphoma Pipeline Insight 2024" report provides comprehensive insights about 50+ Follicular Lymphoma companies and 50+ pipeline drugs in the Follicular Lymphoma pipeline landscape. It covers the Follicular Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Follicular Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Follicular Lymphoma Pipeline Insights Report 2024
DelveInsight's, "Follicular Lymphoma Pipeline Insight 2024" report provides comprehensive insights about 50+ Follicular Lymphoma companies and 50+ pipeline drugs in the Follicular Lymphoma pipeline landscape. It covers the Follicular Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Follicular Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Global Follicular Lymphoma Treatment Industry Opportunities, Analysis & Forecast …
Dhirtek Business Research and Consulting most recent study on the follicular lymphoma treatment market provides a comprehensive view of the entire market. The research report delves deeply into the global follicular lymphoma treatment market's drivers and restraints. Analysts have extensively researched the global follicular lymphoma treatment market's milestones and the current trends that are expected to determine its future. Primary and secondary research methods were used to create an in-depth…
Follicular Unit Extraction (FUE) Systems Market 2021 | Detailed Report
ReportsnReports publishes the report titled Follicular Unit Extraction (FUE) Systems that presents a 360-degree overview of the market under one roof. The report is developed with the meticulous efforts of an enthusiastic and experienced team of experts, analyts, and researchers that makes the report a valuable asset for stakeholders to make robust decisions. This report also provides an in-depth overview of product type, specification, technology, and production analysis considering vital…
